Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Linch

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphomaKarl S Peggs, Irfan Kayani, Noha Edwards, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 30, 2003
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activityKarl S Peggs, Stephen Mackinnon, Catherine D Williams, et al.
British Journal of Haematology|March 6, 2010
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHLDavid C Linch, Lynny Yung, Paul Smith, et al.
Journal of the National Cancer Institute|February 8, 2007
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort studyAnthony J Swerdlow, Craig D Higgins, Paul Smith, et al.
British Journal of Haematology|December 11, 2002
Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortalitySuparno Chakrabarti, Irit Avivi, Stephen Mackinnon, et al.
Blood|June 14, 2005
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 yearsDavid T Bowen, Marion E Frew, Robert Hills, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab eraChristian Gisselbrecht, Bertram Glass, Nicolas Mounier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort studyAnthony J Swerdlow, Craig D Higgins, Paul Smith, et al.
Leukemia & Lymphoma|May 19, 2016
Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208Adriana E Tron, Erika K Keeton, Minwei Ye, et al.
British Journal of Haematology|March 26, 2013
Does BCR/ABL1 positive acute myeloid leukaemia exist?Ellie P Nacheva, Colin D Grace, Diana Brazma, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphomaKarl S Peggs, Irfan Kayani, Noha Edwards, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 30, 2003
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activityKarl S Peggs, Stephen Mackinnon, Catherine D Williams, et al.
British Journal of Haematology|March 6, 2010
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHLDavid C Linch, Lynny Yung, Paul Smith, et al.
Journal of the National Cancer Institute|February 8, 2007
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort studyAnthony J Swerdlow, Craig D Higgins, Paul Smith, et al.
British Journal of Haematology|December 11, 2002
Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortalitySuparno Chakrabarti, Irit Avivi, Stephen Mackinnon, et al.
Blood|June 14, 2005
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 yearsDavid T Bowen, Marion E Frew, Robert Hills, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab eraChristian Gisselbrecht, Bertram Glass, Nicolas Mounier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort studyAnthony J Swerdlow, Craig D Higgins, Paul Smith, et al.
Leukemia & Lymphoma|May 19, 2016
Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208Adriana E Tron, Erika K Keeton, Minwei Ye, et al.
British Journal of Haematology|March 26, 2013
Does BCR/ABL1 positive acute myeloid leukaemia exist?Ellie P Nacheva, Colin D Grace, Diana Brazma, et al.
Pageof 13